Response to the letters to the editor of S. Benkhaled et al. and C.H. Rim regarding the article “Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4–10 brain metastases: A nonrandomized controlled trial” by Bodensohn et al.

We would like to express our sincere gratitude to our colleagues C.H. Rim and S. Benkhaled et al. for their valuable and insightful comments to our paper via their letters [ 1 Bodensohn R. Kaempfel A.L. Boulesteix A.L. et al. Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4–10 brain metastases: A nonrandomized controlled trial. Radiother Oncol: J Eur Soc Therapeut Radiol Oncol. 2023; 186: 109744https://doi.org/10.1016/j.radonc.2023.109744 Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar , 2 Rim C.H. Letter to the Editor of Radiotherapy and Oncology regarding the paper “Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4–10 brain metastases: A nonrandomized controlled trial » by Bodensohn et al.. Radiother Oncol: J Eur Soc Therapeut Radiol Oncol. 2023; ([in press]) Abstract Full Text Full Text PDF Google Scholar , 3 Benkhaled S. Jullian N. Collen C. Letter to the editor regarding the article “Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4–10 brain metastases: A non-randomized controlled trial” by Bodensohn et al.. Radiother Oncol: J Eur Soc Therapeut Radiol Oncol. 2023; ([in press]) Abstract Full Text Full Text PDF Google Scholar ]. Letter to the editor regarding the article “Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4–10 brain metastases: A nonrandomized controlled trial” by Bodensohn et alRadiotherapy and OncologyVol. 189PreviewI read the work of Bodensohn et al [1]. with thankful interest. In a situation where the life expectancy of metastatic cancer patients is increasing, attempts to maintain the quality of life are essential. In the authors' study, the median survival of the stereotactic radiosurgery (SRS) group was 3.3 months longer than that of the control group, with borderline significance (p = 0.074). In the multivariate analysis, the hazard ratio was 0.38 (p = 0.001), showing a benefit of SRS. In randomized studies treating small number of brain metastases, whole brain radiotherapy (WBRT) added to SRS did not improve survival, and might induce cognitive function loss [2–4]. Full-Text PDF Letter to the editor of radiotherapy and oncology regarding the paper “Stereotactic radiosurgery versus whole-brain radiotherapy in patients with 4–10 brain metastases: A nonrandomized controlled trial » by Bodensohn et al.Radiotherapy and OncologyVol. 189PreviewWe read Bodensohn and collegues’ article with interest and we congratulate them. Indeed, brain metastases (BMs) continue to pose challenges in the management of cancer-related neurological complications. Authors aimed to compare historical whole-brain radiation therapy (WBRT) with stereotactic radiosurgery (SRS) in patients with 4–10 brain BMs. While the primary objective of improving median overall survival (OS) for the SRS cohort was not met, adjusting for confounding factors yielded inconsistent results. Full-Text PDF